酷氏基因(Guzip Biomarkers Corporation) 是2018年自臺北醫(yī)學大學衍生的新創(chuàng)公司，專注於表觀遺傳學（Epigenetics）的研究，致力於子宮內(nèi)膜癌的檢驗試劑開發(fā)，為造福女性健康作出貢獻。

Guzip Biomarkers Corporation is a 2018 spin-out company from Taipei Medical University. Our company has put great effort into developing a diagnostic tool for endometrial cancer. Our vision is to be a leading provider dedicated to the women’s healthcare arena, providing accurate, affordable, and safe medical solutions to diagnose endometrial cancer.